{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T22:20:44Z","timestamp":1774995644203,"version":"3.50.1"},"reference-count":58,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Upper tract urothelial carcinoma (UTUC) accounts for 5\u201310% of all UCs. Immune checkpoint inhibitors (ICIs) have been established for UCs. The prognostic and predictive potential of programmed cell death ligand 1 (PD-L1) expression to stratify patients benefiting from ICIs is not fully understood, and additional markers influencing the impact of PD-L1-mediated ICI response are needed. Previously, the chemokine-like MARVEL transmembrane domain-containing protein 6 (CMTM6) was identified as a positive regulator of PD-L1. Our aim was to investigate the expression profiles and impact of PD-L1 and CMTM6 protein status on the prognostic parameters and survival of UTUC patients. In this retrospective study, the combined positive score (CPS), tumor proportion score (TPS), and immune cell score (ICS) for PD-L1 and CMTM6 were determined. High PD-L1 CPS, ICS, and TPS were found in 77.4%, 58.3%, and 45.2% of cases, and high CMTM6 CPS, ICS, and TPS were seen in 52.5%, 51.5%, and 55.5% of cases, respectively. The scores of both markers had a significant positive correlation. High PD-L1 and CMTM6 expression was coupled with higher pT status, WHO grade, necrosis, and metastasis (p &lt; 0.05, respectively). In the univariate survival analysis, patients with a PD-L1 ICS high and higher degree of intratumoral inflammation showed significantly longer overall survival. Compared to other studies on UC, our study shows a substantially higher rate of PD-L1-positive tumors. CMTM6 was associated with more aggressive tumors.<\/jats:p>","DOI":"10.3390\/ijms25063492","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:04:12Z","timestamp":1710911052000},"page":"3492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-7847","authenticated-orcid":false,"given":"Said","family":"Kdimati","sequence":"first","affiliation":[{"name":"Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Christoph","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c4nne","family":"Glass","sequence":"additional","affiliation":[{"name":"Institute of Biostatistics and Informatics in Medicine and Aging Research, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-9282","authenticated-orcid":false,"given":"Nadja","family":"Engel","sequence":"additional","affiliation":[{"name":"Department of Oral, Maxillofacial and Plastic Surgery, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desiree-Louise","family":"Dr\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Urology, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-8439","authenticated-orcid":false,"given":"Claudia","family":"Maletzki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical Clinic III\u2014Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-2986","authenticated-orcid":false,"given":"Anne-Sophie","family":"Becker","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Zimpfer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Rostock University Medical Center, 18057 Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","article-title":"Upper urinary tract urothelial cell carcinoma: Location as a predictive factor for concomitant bladder carcinoma","volume":"31","author":"Cosentino","year":"2013","journal-title":"World J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.eururo.2012.02.042","article-title":"Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence","volume":"61","author":"Xylinas","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.eururo.2009.12.032","article-title":"Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma","volume":"57","author":"Li","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000457133","article-title":"Upper Urinary Tract Tumors: Which Diagnostic Methods Are Needed?","volume":"98","author":"Maruschke","year":"2017","journal-title":"Urol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","volume":"84","author":"Seisen","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.21037\/tau-23-45","article-title":"Diagnosis, workup, and risk stratification of upper tract urothelial carcinoma","volume":"12","author":"Zganjar","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.2147\/CMAR.S180606","article-title":"Microscopic hematuria predicts lower stage in patients with upper tract urothelial carcinoma","volume":"10","author":"Qi","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update","volume":"73","author":"Babjuk","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.urology.2016.04.030","article-title":"Diagnostic Utility of Selective Upper Tract Urinary Cytology: A Systematic Review and Meta-analysis of the Literature","volume":"96","author":"Potretzke","year":"2016","journal-title":"Urology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00345-019-02875-8","article-title":"Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): A systematic review and meta-analysis","volume":"38","author":"Janisch","year":"2020","journal-title":"World J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2214\/ajr.184.6.01841873","article-title":"MDCT urography of upper tract urothelial neoplasms","volume":"184","author":"Caoili","year":"2005","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000019869","article-title":"Conventional CT signs in staging transitional cell tumors of the upper urinary tract","volume":"35","author":"Palou","year":"1999","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejrad.2017.10.021","article-title":"Upper tract urothelial cancer","volume":"98","author":"Froemming","year":"2018","journal-title":"Eur. J. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update","volume":"79","author":"Babjuk","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): A phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"ref_19","unstructured":"Cancer Research Institute (2023, March 23). FDA Approval Timeline of Active Immunotherapies: CRI. Available online: https:\/\/www.cancerresearch.org\/?s=FDA+Approval+Timeline+of+Active+Immunotherapies."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","article-title":"Der pr\u00e4diktive Wert der PD-L1-Diagnostik","volume":"39","author":"Schildhaus","year":"2018","journal-title":"Pathologe"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3389\/fonc.2020.01400","article-title":"The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis","volume":"10","author":"Lu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12032-017-0941-2","article-title":"Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma","volume":"34","author":"Zhang","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.juro.2017.06.086","article-title":"Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma","volume":"198","author":"Krabbe","year":"2017","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2023.01.016","article-title":"Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score","volume":"83","author":"Galsky","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","article-title":"Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder","volume":"40","author":"Xylinas","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1\/2 Open-label Study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, in Patients with Refractory Metastatic Urothelial Carcinoma: Results from a Multicenter, Phase Ib Study","volume":"35","author":"Apolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.jtho.2019.09.014","article-title":"Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer","volume":"14","author":"Zugazagoitia","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/2326-6066.CIR-19-0394","article-title":"Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13330","DOI":"10.1002\/jcb.28607","article-title":"An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade","volume":"120","author":"Zhao","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-020-02741-2","article-title":"OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1\/2 signaling pathway","volume":"70","author":"Pang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Evmorfopoulos, K., Mitrakas, L., Karathanasis, A., Zachos, I., Tzortzis, V., and Vlachostergios, P.J. (2023). Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071775"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bju.16129","article-title":"Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma","volume":"132","author":"Campedel","year":"2023","journal-title":"BJU Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.euf.2016.11.011","article-title":"Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma","volume":"3","author":"Skala","year":"2017","journal-title":"Eur. Urol. Focus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bju.15341","article-title":"CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma","volume":"128","author":"Tulchiner","year":"2021","journal-title":"BJU Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clon.2017.10.019","article-title":"The Role of PD-1 Positivity in the Tumour Nest on Clinical Outcome in Upper Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy","volume":"30","author":"Hayakawa","year":"2018","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100159","DOI":"10.1016\/j.modpat.2023.100159","article-title":"Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test","volume":"36","author":"Fernandez","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"154042","DOI":"10.1016\/j.prp.2022.154042","article-title":"PD-L1 expression in head and neck cancer tissue specimens decreases with time","volume":"237","author":"Karpathiou","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s00262-021-02931-6","article-title":"CMTM6 expression in M2 macrophages is a potential predictor of PD-1\/PD-L1 inhibitor response in colorectal cancer","volume":"70","author":"Wu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"585961","DOI":"10.3389\/fonc.2020.585961","article-title":"Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ebiom.2018.08.012","article-title":"CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas","volume":"35","author":"Guan","year":"2018","journal-title":"eBioMedicine"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Becker, A.-S., Kluge, C., Schofeld, C., Zimpfer, A.H., Schneider, B., Str\u00fcder, D., Redwanz, C., Ribbat-Idel, J., Idel, C., and Maletzki, C. (2023). Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response. Cancers, 15.","DOI":"10.3390\/cancers15235597"},{"key":"ref_57","unstructured":"Mostofi, F.K., Sobin, L.H., and Torloni, H. (1973). International Histological Classification of Tumors, World Health Organization."},{"key":"ref_58","unstructured":"Williamson, S.R., Al-Ahmadie, H.A., Cheng, L., Downes, M.R., Lopez-Beltran, A., Narumi, Y., Panebianco, V., Paner, G.P., Raspolllini, M.R., and Ro, J.Y. (2022). Urinary and Male Genital Tumours, International Agency for Research on Cancer. [5th ed.]."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:16:27Z","timestamp":1760105787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25063492"],"URL":"https:\/\/doi.org\/10.3390\/ijms25063492","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]}}}